Tonix Pharmaceuticals Presented Poster Of Tonmya For The Management Of Fibromyalgia At The Annual EULAR 2024
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented positive Phase 3 study results for Tonmya in managing fibromyalgia at the EULAR 2024 conference. The study showed significant pain reduction and symptom improvement, with an NDA submission to the FDA expected in the second half of 2024.
June 17, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals presented positive Phase 3 results for Tonmya in managing fibromyalgia, showing significant pain reduction and symptom improvement. An NDA submission to the FDA is expected in the second half of 2024.
The positive Phase 3 results and the upcoming NDA submission are likely to boost investor confidence and positively impact TNXP's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100